Case Study

Oxford Cancer Biomarkers (OCB): Combining leading-edge diagnostics with AI technology to improve outcomes for cancer patients

Oxford Cancer Biomarkers (OCB): Combining leading-edge diagnostics with AI technology to improve outcomes for cancer patients

Pages 4 Pages

Share this Formed as a spin-out from the University of Oxford, Oxford Cancer Biomarkers aims to enable early prediction of cancer risk and increased precision of cancer treatment to drive personalized medicine. It does this through the use of platforms incorporating biomarker-based technology from its research and development teams and partners. Business challenge OCB recognized that hundreds of thousands of lives and billions of dollars could be saved in Europe alone by detecting colorectal cancer sooner and reducing unnecessary overtreatment with chemotherapy. Transformation Working with Meridian IT to deploy IBM® PowerAI Vision running on IBM Power SystemsTM servers, OCB accelerated analysis of digital images of tumors to determine the risk of recurrence of colorectal cancer.

Join for free to read